NCT05868330 Comparison of Interscalene Catheter to Single Injection Interscalene Blocks for Total Shoulder Arthroplasties
| NCT ID | NCT05868330 |
| Status | Recruiting |
| Phase | Phase 4 |
| Sponsor | Melinda Seering |
| Condition | Post Operative Pain |
| Study Type | INTERVENTIONAL |
| Enrollment | 56 participants |
| Start Date | 2024-08-19 |
| Primary Completion | 2026-10 |
Eligibility & Interventions
Eligibility Fast-Check
Enter your details for a quick preliminary check. This does not replace medical advice.
What to Expect as a Participant
You will actively receive the study intervention — which may be a drug, biologic, device, or procedure.
Phase 4 studies follow an already-approved treatment in real-world conditions to monitor long-term safety and effectiveness.
This trial targets 56 participants in total. It began in 2024-08-19 with a primary completion date of 2026-10.
⚠ This information is for research awareness only. Always consult your physician before joining any clinical trial. Participation is voluntary and you may withdraw at any time.
Brief Summary
Comparison of post-operative pain after total shoulder surgery. The Principle Investigator will be comparing Exparel single shot block to Interscalene catheter
Eligibility Criteria
Inclusion Criteria: Patients who have or are: 1. Orthopedics service patients having reverse shoulder replacement surgery 2. ASA class I, II, or III. 3. Patients at least 18 years old but less than 90 years old. 4. Patients giving informed consent. 5. Non-Emergency Surgery Exclusion Criteria: Patients who have or are: 1. An inability to cooperate during the block placement. 2. Patients who do not meet criteria for a regional block: such as those on anti-coagulation, 3. Significant pulmonary disease or allergy to medications used for peripheral nerve blocks (Exparel, Bupivacaine and Ropivacaine) 4. Neuropathy of the planned extremity to block 5. Documented Kidney Failure 6. Documented Liver Failure 7. A lack of or inability to give informed consent. 8. Currently incarcerated. 9. Pregnant 10. Unable to communicate in English 11. Chronic pre-operative opioid use (greater than 20 MME opioid used) 12. Fracture 13. Revision surgery
Contact & Investigator
Melinda Seering, MD
PRINCIPAL INVESTIGATOR
University of Iowa
Frequently Asked Questions
Who can join the NCT05868330 clinical trial?
This trial is open to participants of all sexes, aged 18 Years or older, up to 90 Years, studying Post Operative Pain. Full inclusion and exclusion criteria are listed in the Eligibility Criteria section. Always confirm your eligibility with the research team before applying.
What phase is the NCT05868330 trial and what does that mean for participants?
Phase 4 studies are conducted after a treatment has been approved. They monitor long-term safety and real-world effectiveness in a broader patient population.
Is NCT05868330 currently recruiting?
Yes, NCT05868330 is actively recruiting participants. Contact the research team at melinda-seering@uiowa.edu for enrollment information.
Where is the NCT05868330 trial being conducted?
This trial is being conducted at Iowa City, United States.
Who is sponsoring the NCT05868330 clinical trial?
NCT05868330 is sponsored by Melinda Seering. The principal investigator is Melinda Seering, MD at University of Iowa. The trial plans to enroll 56 participants.